IMU 9.26% 5.9¢ imugene limited

Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-29

  1. 97 Posts.
    lightbulb Created with Sketch. 31
    Interestingly we now have our own manufacturing facility as well...

    Imugene will also acquire the lease to a state-of-the art 32,800 sq feet GMP
    manufacturing facility in North Carolina, drug material for completion of a Phase 1b clinical
    trial and a highly experienced cell therapy and manufacturing team of approximately 50
    personnel
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.